Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amgen Inc. (AMGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer and a component of the Dow Jones Industrial Average and Nasdaq-100 Index, Amgen uses SEC filings to report financial results, material events and other information relevant to shareholders.
Amgen’s Form 8-K filings illustrate how the company communicates quarterly performance. For example, 8-K reports dated August 5, 2025 and November 4, 2025 describe second and third quarter earnings press releases, including unaudited results of operations and financial position. These filings also explain Amgen’s use of non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and Free Cash Flow. The company outlines which acquisition-related expenses, restructuring charges and other items are excluded from GAAP results and how the related tax effects are calculated.
On this page, users can review Amgen’s current and historical SEC documents, including Forms 10-K and 10-Q when available, 8-Ks for earnings and other material events, and additional filings that may address debt offerings, governance matters or other disclosures. Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly understand topics such as segment performance, non-GAAP adjustments, liquidity metrics and risk factor discussions without reading every page.
The filings page also surfaces information relevant to questions about AMGN stock, such as how management describes its financial performance, what non-GAAP metrics it emphasizes and how it discusses acquisition-related charges and restructuring initiatives. Real-time updates from EDGAR, combined with AI-generated overviews, allow investors to follow new Amgen filings as they appear and to place each document in the context of the company’s broader financial and regulatory history.
Amgen Inc. executive Esteban Santos, EVP of Operations, reported compensation-related share activity in Common Stock. On May 2, 2026, he had 1,338 shares withheld as a tax-withholding disposition in two F-code transactions at $329.82 per share, a non‑market mechanism used to satisfy tax obligations on equity awards rather than an open-market sale. He also reported 909.9906 shares held indirectly through the Company’s 401(k) Plan, representing interests in Amgen’s stock fund.
Amgen Inc. executive David M. Reese reported routine tax-related share dispositions. On May 2, 2026, a total of 1,433 shares of Amgen common stock were withheld at $329.82 per share to cover tax obligations, classified as tax-withholding dispositions rather than open-market sales.
A footnote notes that the reported holdings include 442 Dividend Equivalents tied to unvested Restricted Stock Units, which will be paid in common shares on a one-to-one basis as those units vest.
Amgen Inc. senior vice president of human resources Derek Miller reported routine share dispositions tied to tax withholding, not open-market sales. On May 2, 2026, a total of 365 shares of Amgen common stock were withheld at $329.82 per share to cover tax liabilities on equity awards.
A footnote explains that his holdings include 123 Dividend Equivalents credited under Amgen’s equity incentive plan, which will be paid out as common shares on a one-for-one basis as related restricted stock units vest.
Amgen Inc. SVP Rachna Khosla reported routine tax-withholding share dispositions. On May 2, 2026, a total of 225 shares of Amgen common stock were withheld at $329.82 per share to cover tax liabilities tied to equity awards, not as open-market sales. She continues to hold a direct stake in Amgen stock, and her holdings also reflect 73 dividend equivalents linked to unvested restricted stock units that will settle in shares as they vest.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported multiple transactions in the company’s common stock. On May 4, 2026, she completed an open-market sale of 1,237 shares at an average price of $323.7272 per share. On May 2, 2026, two F-code tax-withholding dispositions of 116 and 126 shares at $329.82 per share were recorded to cover tax obligations. After these transactions, she directly holds 7,009 shares of Amgen common stock and has an additional 106.1864 shares indirectly through the company’s 401(k) Plan. Her holdings also reflect 72 Dividend Equivalents tied to unvested restricted stock units that pay out in shares as they vest.
Amgen Inc. EVP & CFO Peter H. Griffith reported two tax-related share dispositions of company common stock. On May 2, 2026, he delivered 687 shares and 746 shares of Amgen stock at $329.82 per share each as tax-withholding transactions, not open-market sales.
After these dispositions, his reported direct holdings in Amgen common stock were 47,568 shares following one transaction and 48,255 shares following the other. A footnote notes that his holdings include 454 Dividend Equivalents tied to unvested Restricted Stock Units under Amgen’s equity incentive plan, which pay out in shares as the awards vest.
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported two routine tax-related share dispositions. On May 2, 2026, a total of 1,257 shares of Amgen common stock were withheld at $329.82 per share to satisfy tax obligations on equity awards, rather than sold on the open market. Following these transactions, his reported direct holdings in the affected accounts were 38,010 and 38,620 shares of common stock.
Amgen Inc. executive Gordon Murdo reported routine tax-related share dispositions, not open-market sales. On May 2, 2026, he had 1,593 shares of common stock withheld at $329.82 per share to cover tax obligations. Following these transactions, he directly holds 49,462 Amgen shares.
A footnote explains his holdings include 488 Dividend Equivalents tied to unvested Restricted Stock Units under Amgen’s equity incentive plan, which pay out in shares according to the vesting schedule.
Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported routine share dispositions related to tax withholding. On May 2, 2026, a total of 68 shares of common stock were withheld at $329.82 per share to satisfy tax obligations tied to equity awards.
Following these transactions, Busch directly holds 4,018 shares of Amgen common stock. A footnote explains that his holdings include 49 Dividend Equivalents linked to unvested Restricted Stock Units, which will be settled in common shares as those units vest.
AMGEN INC Chairman, CEO and President Robert A. Bradway reported routine equity-related activity in company stock. The filing shows tax-withholding dispositions totaling 5,057 shares of common stock at $329.82 per share, used to cover exercise price or tax liabilities tied to equity awards.
Bradway also reports indirect holdings in Amgen common stock through his spouse and related GRATs, alongside Dividend Equivalents credited to unvested Restricted Stock Units that pay out in shares as they vest. These transactions do not reflect open-market buying or selling decisions.